Author
Editor-At-Large
Immunovant hires legal chief
Mark Levine was most recently general counsel and corporate secretary of Flexion Therapeutics
Nasdaq-listed Immunovant has appointed Mark Levine as chief legal officer (CLO).
Levine was most recently general counsel and corporate secretary of Flexion Therapeutics, a commercial-stage biopharmaceutical company, where he was responsible for overseeing legal and compliance affairs related to Flexion’s 2017 launch of ZILRETTA in the US and building its pipeline. Flexion was ultimately acquired by Pacira BioSciences in late 2021.
Levine was previously general counsel and corporate secretary at Minerva Neurosciences and associate general counsel at Clinical Data. His legal experience includes advising on M&A and divestitures, licensing agreements and partnerships and development and commercialization.
Immunovant is a clinical-stage biopharmaceutical company focused on autoimmune diseases.
CEO Pete Salzmann says in a statement: ‘We are extremely pleased to welcome Mark Levine as Immunovant’s [CLO]. Mark’s broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization will enhance our existing capabilities as we plan to initiate pivotal trials for [product candidate] batoclimab in 2022.’
Appointments
Elisa Garcia, executive vice president, chief legal officer (CLO) and corporate secretary of Macy’s, has informed the company that she plans to...Read more
NYSE-listed Everest Re Group has recruited Ricardo Anzaldua to become executive vice president and group general counsel, effective June 12. He will...Read more
Stephen Allen, senior vice president, general counsel and assistant secretary with ONEOK, will retire in mid-August 2023 having spent more than 17...Read more
NYSE-listed Albertsons Companies has recruited Tom Moriarty to become executive vice president and general counsel, effective June 5. He will report...Read more
